# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developi...
In April 2024, the Company submitted a briefing book to the FDA to help guide the next steps in the clinical development pathwa...
The Leidos team's Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company's Proprietary T...
- SEC Filing
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial. 6 out of 6 Patients Who Completed the 12-...
TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.40) per share which missed the analyst consensus estimate of...